Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/30104% above fair value
$168.08+0.13 (+0.08%)
Close on Nov 13, 2026Market cap $208.48BP/E –Yield 1.88%
Gilead Sciences cash
Cash and short-term investments held at the end of each period.
Gilead Sciences's cash was $6.44B at Sep 30, 2026. For fiscal 2025 it was $7.63B, down 23.6% from the year before. Over ten years it grew -6.3% a year on average. The highest annual figure on record is $30.09B in fiscal 2018.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.63B | -23.6% |
| FY2024 | Dec 31, 2024 | $9.99B | +37.5% |
| FY2023 | Dec 31, 2023 | $7.26B | +13.8% |
| FY2022 | Dec 31, 2022 | $6.39B | -2.1% |
| FY2021 | Dec 31, 2021 | $6.52B | -12.0% |
| FY2020 | Dec 31, 2020 | $7.41B | -69.6% |
| FY2019 | Dec 31, 2019 | $24.35B | -19.1% |
| FY2018 | Dec 31, 2018 | $30.09B | +17.9% |
| FY2017 | Dec 31, 2017 | $25.51B | +114.5% |
| FY2016 | Dec 31, 2016 | $11.90B | -18.6% |
| FY2015 | Dec 31, 2015 | $14.61B | +44.2% |
| FY2014 | Dec 31, 2014 | $10.13B | +375.0% |
| FY2013 | Dec 31, 2013 | $2.13B | +14.5% |
| FY2012 | Dec 31, 2012 | $1.86B | -81.2% |
| FY2011 | Dec 31, 2011 | $9.90B | +371.8% |
| FY2010 | Dec 31, 2010 | $2.10B | +26.7% |
| FY2009 | Dec 31, 2009 | $1.66B | -7.4% |
| FY2008 | Dec 31, 2008 | $1.79B | +84.9% |
| FY2007 | Dec 31, 2007 | $968.09M | +18.6% |
| FY2006 | Dec 31, 2006 | $816.01M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $6.44B | -12.4% |
| Q2 FY2026 | Jun 30, 2026 | $3.18B | -39.0% |
| Q1 FY2026 | Mar 31, 2026 | $7.64B | -3.6% |
| Q4 FY2025 | Dec 31, 2025 | $7.63B | -23.6% |
| Q3 FY2025 | Sep 30, 2025 | $7.35B | +45.9% |
| Q2 FY2025 | Jun 30, 2025 | $5.21B | +88.1% |
| Q1 FY2025 | Mar 31, 2025 | $7.93B | +68.0% |
| Q4 FY2024 | Dec 31, 2024 | $9.99B | +37.5% |
| Q3 FY2024 | Sep 30, 2024 | $5.04B | -26.6% |
| Q2 FY2024 | Jun 30, 2024 | $2.77B | -58.4% |
| Q1 FY2024 | Mar 31, 2024 | $4.72B | -19.7% |
| Q4 FY2023 | Dec 31, 2023 | $7.26B | +13.8% |
| Q3 FY2023 | Sep 30, 2023 | $6.86B | +21.3% |
| Q2 FY2023 | Jun 30, 2023 | $6.67B | +17.7% |
| Q1 FY2023 | Mar 31, 2023 | $5.87B | +10.3% |
| Q4 FY2022 | Dec 31, 2022 | $6.39B | -2.1% |
| Q3 FY2022 | Sep 30, 2022 | $5.66B | -1.4% |
| Q2 FY2022 | Jun 30, 2022 | $5.66B | -13.2% |
| Q1 FY2022 | Mar 31, 2022 | $5.33B | -6.0% |
| Q4 FY2021 | Dec 31, 2021 | $6.52B | -12.0% |
| Q3 FY2021 | Sep 30, 2021 | $5.74B | -76.1% |
| Q2 FY2021 | Jun 30, 2021 | $6.53B | -65.5% |
| Q1 FY2021 | Mar 31, 2021 | $5.67B | -72.7% |
| Q4 FY2020 | Dec 31, 2020 | $7.41B | -69.6% |
| Q3 FY2020 | Sep 30, 2020 | $23.98B | +4.9% |
| Q2 FY2020 | Jun 30, 2020 | $18.91B | -30.4% |
| Q1 FY2020 | Mar 31, 2020 | $20.79B | -25.5% |
| Q4 FY2019 | Dec 31, 2019 | $24.35B | -19.1% |
| Q3 FY2019 | Sep 30, 2019 | $22.86B | -19.7% |
| Q2 FY2019 | Jun 30, 2019 | $27.18B | +4.9% |
| Q1 FY2019 | Mar 31, 2019 | $27.90B | +16.3% |
| Q4 FY2018 | Dec 31, 2018 | $30.09B | +17.9% |
| Q3 FY2018 | Sep 30, 2018 | $28.47B | +0.3% |
| Q2 FY2018 | Jun 30, 2018 | $25.92B | +22.9% |
| Q1 FY2018 | Mar 31, 2018 | $24.00B | +70.0% |
| Q4 FY2017 | Dec 31, 2017 | $25.51B | +114.5% |
| Q3 FY2017 | Sep 30, 2017 | $28.39B | – |
| Q2 FY2017 | Jun 30, 2017 | $21.10B | – |
| Q1 FY2017 | Mar 31, 2017 | $14.12B | – |
| Q4 FY2016 | Dec 31, 2016 | $11.90B | – |
See a number that looks wrong?